Novartis remains committed to promoting health equity and patient-centered care. An example of this is the More Than Just Words initiative, focused on encouraging more productive, empathetic, and unbiased conversations about breast cancer risk, diagnosis and care among health care providers and patients to help improve breast cancer outcomes for Black women. We are bringing this to life with a virtual reality experience that puts us in the shoes of Black women along the breast cancer continuum of care. The VR tool features different scenarios that are based on real-life patient experiences, helping users identify unconscious bias and opportunities for more empathetic care for these patients. Join us at #ASCO2024 to learn more about our efforts in breast cancer health equity. Novartis Oncology
Novartis Oncology
Arzneimittelherstellung
Basel, Switzerland 275.244 Follower:innen
Reimagining medicine by transforming cancer
Info
At Novartis, our mission is to discover new ways to improve and extend people's lives. We use science-based innovation to address some of society's most challenging healthcare issues. We discover and develop breakthrough treatments and find new ways to deliver them to as many people as possible. At Novartis, we focus on five key cancer areas where we have identified patient needs and promise within our portfolio - breast cancer, lung cancer, melanoma, kidney cancer and hematology. As a leader in oncology, Novartis offers a portfolio treating more than 25 conditions worldwide and approximately 30 compounds in development. We are passionate about what we do and the impact we have on patients and societies. We are Novartis, and we are reimagining medicine. See our community guidelines:https: https://bit.ly/3yAl483
- Website
-
https://www.novartis.com/about/therapeutic-areas/oncology
Externer Link zu Novartis Oncology
- Branche
- Arzneimittelherstellung
- Größe
- 10.001+ Beschäftigte
- Hauptsitz
- Basel, Switzerland
- Art
- Kapitalgesellschaft (AG, GmbH, UG etc.)
- Spezialgebiete
- Research, Innovation, Oncology, Hematology, Immunooncology und Quality
Orte
-
Primär
Wegbeschreibung
Novartis Campus
Basel, Switzerland 4056, CH
-
Wegbeschreibung
1 Health Plaza
East Hanover, New Jersey 07936, US
-
Wegbeschreibung
1 Health Plaza
East Hanover, NJ 07936, US
-
Wegbeschreibung
3 El Sawah Street
Cairo, Cairo, EG
Beschäftigte von Novartis Oncology
Updates
-
1.2 to 1.5 million people are currently living with chronic myeloid leukemia (CML) worldwide. This new data may offer hope to those living with this difficult disease, advancing our mission to #reimaginemedicine for these patients. #ASCO24
This #ASCO2024, we are proud to present data from our Phase III ASC4FIRST trial for patients with newly diagnosed chronic myeloid leukemia (CML). While advances in CML treatment have enhanced patient outcomes, unmet need remains, with many newly diagnosed patients not meeting treatment goals and many discontinuing or changing treatment due to intolerance. Novartis is committed to working with the CML community to #reimaginemedicine for these patients.
-
Novartis Oncology hat dies direkt geteilt
The Novartis "More Than Just Words" initiative was created in collaboration with a diverse team of experts - including patients, advocates, and healthcare professionals - to address the most pressing issues affecting racial disparities in breast cancer care. Patients, practitioners, health care leaders and members of the industry -- we all have a role to play in helping close the serious gap in care faced by Black women. Let’s work together to address disparities in breast cancer care and #ReimagineMedicine for all. To learn more, visit www.MoreThanJustWords.US or visit us at #ASCO2024. Novartis Oncology
-
-
Today we announce the FDA approval of a radioligand therapy for pediatric patients living with gastroenteropancreatic neuroendocrine tumors (GEP-NETs). This is the first therapy specifically approved for pediatric patients with this rare cancer, and represents our ongoing commitment to developing the RLT platform across multiple cancer types and treatment settings. https://lnkd.in/e5mgsaBE
-
-
This #ENETS24 we're pleased to be presenting our encore data from the NETTER-2 trial exploring a radioligand therapy (#RLT) in a first-line setting for patients with grade 2 and grade 3 metastatic GEP-NETs. Find more about the advancements in this space here: https://lnkd.in/ezStpJgw #NeuroendocrineCancer
-
#NeuroendocrineTumors (#NETs) are rare types of cancers and the majority (over 60%) originate in the digestive system – these are called gastroenteropancreatic neuroendocrine tumors, or GEP-NETs. The journey to diagnosis is often long and takes a toll on patients’ overall wellbeing. On average, it can take over four years from first onset of symptoms to a final diagnosis, after an extensive medical journey, including several examinations and multiple specialists. Unfortunately, such delays mean that the majority of patients are initially diagnosed with advanced disease. At Novartis, we are dedicated to discovering new ways to improve health outcomes for patient communities with clear unmet needs. Join us at the European Neuroendocrine Tumor Society e.V. (ENETS) congress to learn more about our commitment to exploring first-line treatment options for patients with grade 2 and grade 3 metastatic GEP-NETs. Learn more about #NeuroendocrineCancer during #ENETS24: http://ms.spr.ly/6043c91rP
NETs can often be misdiagnosed
-
GEP-NETs are a diverse and heterogeneous group of tumors with often vague and non-specific symptoms leading to delays in diagnosis. People diagnosed with this type of cancer often express somatostatin receptors on their tumor cells or tumor microenvironment. Radioligand therapy (#RLT) targets these receptors on cancer cells or tumor microenvironment, to destroy or damage them, with the goal of limiting impact on healthy tissues. Hear from us at the European Neuroendocrine Tumor Society e.V. (ENETS) congress as we present findings that explore the use of RLT as a potential first-line treatment in metastatic GEP-NETs. Learn more about radioligand therapies here: http://ms.spr.ly/6042c91Ru #ENETS24
Future of cancer care
-
Today at ASCO-GI, we announced the first set of Phase III data for a radioligand therapy (RLT) in the first-line setting. We’re proud to share the late-breaking results from the NETTER-2 trial https://lnkd.in/gXh7jvhd
Novartis News
novartis.com
-
What happens #BehindTheGlassAtNVS? At our #RadioligandTherapy (RLT) manufacturing facilities, highly specialized associates race against the clock every day as they seek to advance our mission to #ReimagineMedicine for the patients who need it. Learn more about the process—and what it means to the people at the heart of it. https://lnkd.in/gaWyq8TS
-
#RadioligandTherapy (RLT) manufacturing operates on a timeline of just hours and days. It’s an intricate process requiring not just precision but also urgency—enabling these medicines to reach the patients who need them. Go #BehindTheGlassAtNVS to see the process firsthand. https://lnkd.in/gBWQwdG4